Antibiotic use in cystic fibrosis.
Antibiotic administration is the mainstay of therapy for pulmonary disease in patients with cystic fibrosis (CF). The progressive nature of the pulmonary disease in CF shortens survival. New and potent antibiotics, more aggressive antibiotic therapy, and multiple routes of administration have contributed to improved survival among CF patients. Pseudomonas aeruginosa is the predominant bacterial pathogen in the lower airways of CF patients. Most of the efforts in treating the chronic pulmonary infection are directed toward this organism. Aerosol aminoglycoside delivery provides a safe and effective alternative method to parenteral administration for treating patients who require chronic antibiotic therapy. This article reviews strategies for choosing antibiotics and current opinions regarding antibiotic therapy for patients with CF.
Eisenberg
J D
JD
Pediatric Pulmonary Division-UHN56, Oregon Health Sciences University, Portland 97201, USA.
D000336:Aerosols; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002908:Chronic Disease; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000382:microbiology; D018450:Disease Progression; D004359:Drug Therapy, Combination / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007275:Injections, Intravenous; D011552:Pseudomonas Infections / Q000188:drug therapy; D011550:Pseudomonas aeruginosa; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D012449:Safety; D015996:Survival Rate
D000336:Aerosols; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents